Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF). Although JAK1/2 inhibitor therapy is effective in decreasing the burden of symptoms associated with splenomegaly and MF-related constitutional symptoms, it is neither curative nor effective in reducing the risk of leukemic transformation. Presently, allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for MF. A significant risk of regimen-related toxicities, graft failure, and GVHD are major barriers to the success of HCT in MF. Because of significant HCT-associated morbidity and mortality, divergent opinions regarding its appropriate role in this clinical situation have emerged. In this review, the risk-benefit ratios of modern drug therapy compared with HCT in MF patients are analyzed. A risk-adapted approach individualized to each patient's biologic characteristics and comorbidities is described, which is currently warranted in determining optimal treatment strategies for patients with MF. Inclusion of JAK1/2 inhibitor therapy in future transplant conditioning regimens may provide an opportunity to overcome some of these barriers, resulting in greater success with HCT for MF patients.
Princess Margaret Hospital, University of Toronto, Ontario, Canada. vikas.gupta@uhn.ca.
Vikas
V
Gupta
Parameswaran
P
Hari
Ronald
R
Hoffman
D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053613:Janus Kinase 1 / Q000037:antagonists & inhibitors*; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors; D053613:Janus Kinase 1